Labiotech.eu

Innate Pharma lirilumab leukemia failure

News and Trends 6 Feb 2017

French Biotech’s Checkpoint Inhibitor Fails Phase II Leukemia Trial

Innate Pharma’s checkpoint inhibitor candidate lirilumab missed its primary endpoint in a Phase II trial, which gave a hard blow to the company’s stock. When the stock market opened this morning, Innate Pharma‘s stock went down by almost 25%. The company had just announced the results of a Phase II trial that failed to prove its […]

February 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 6 Feb 2017

“We want to be the Worldwide Leader in Microbiota”

Biotech entrepreneur Hervé Affagard, CEO of MaaT Pharma, tells the story behind the success of his young microbiome company. Hervé Affagard is the CEO and co-founder of a company with an ambitious goal: become the global leader in treating the gut microbiota. Founded in 2014 and based in Lyon, MaaT pharma wants to employ fecal transplants to treat […]

February 6, 2017 - 5 minutesmins - By Clara Rodríguez Fernández

More News! 4 Feb 2017

This PhD-Carrying Musician Tells the Story of Life through Music & Video

Max Cooper bridges the age-old divide between science and art with a transfixing blend of glitchy electronica, classical music and haunting vocals. I was lucky enough to catch Max Cooper live in Dublin last weekend, during his tour to showcase his latest album, Emergence. Inspired by natural processes and the laws underlying them, Emergence is a tour-de-force of […]

February 4, 2017 - 6 minutesmins - By Evelyn Warner

genetically modified insects gmo organic food

News and Trends 3 Feb 2017

Could GM Insects impact the international trade of Organic Food?

Genetically modified insects are released to control the spread of diseases and crop pests, but the logistics may not be so simple: these little creatures could jam global food exports, particularly to more GM-averse Europe. What happens when genetically engineered insects develop on vegetable farms? Two researchers, from the Max Planck Institue for Evolutionary Biology in […]

February 3, 2017 - 3 minutesmins - By Denise Neves Gameiro

More News! 2 Feb 2017

Galapagos kicks off a Phase IIa trial for Cystic Fibrosis

After Galapagos and AbbVie expanded their collaboration on cystic fibrosis, Galapagos now announces the start of their Phase IIa trial for a novel cystic fibrosis corrector. Since entering their collaboration with AbbVie on cystic fibrosis (CF) in 2013, Galapagos has received almost €40M in milestone payments from AbbVie. Galapagos now announced the start of a Phase […]

February 2, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 1 Feb 2017

Young Belgian Biotech will tackle Fibrosis with a New Grant

Confo Therapeutics has received a €1.6M grant to support the discovery of drugs against fibrosis, one of the most deadly conditions in Western countries. Confo Therapeutics is a young biotech in Brussels developing a unique technology to target historically undruggable G protein-coupled receptors (GPCRs). The company just announced it received a €1.6M grant from Flanders Innovation & […]

February 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 1 Feb 2017

Meet these 3 Exciting German Startups Pitching in Aachen Today!

Today is Life Science Pitch Day in Aachen! High-Tech Gründerfonds has invited a handful of startups in the seed and Series A stages to make their pitches to investors this afternoon. Here are three of the companies who you’ll hear speak! cytena cytena, a spinoff from the University of Freiburg, is improving current methods in […]

February 1, 2017 - 3 minutesmins - By Evelyn Warner

News and Trends 1 Feb 2017

Young German Immune Therapy Biotech expands its Series A Funding

Immunic Therapeutics has received an extra €4M that will be directed at speeding the development of treatments for Crohn’s disease and psoriasis. Immunic Therapeutics is a young company based in Munich’s biotech hub that develops immune therapies for chronic inflammatory diseases. Today, it announced a €4M investment from IBG, which increases its Series A financing to a […]

February 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 1 Feb 2017

Stem Cell Therapy for Sepsis in Pneumonia advances to Phase II

TiGenix has treated the first patient in a new early-stage clinical trial to test its candidate Cx611 as a treatment for sepsis in patients with pneumonia. TiGenix, based in Belgium, develops stem cell therapies derived from donors. This morning, the first patient was treated in a Phase Ib/IIa clinical trial for its candidate therapy Cx611 in […]

February 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 31 Jan 2017

New British Biotech-Academia Alliance takes on Cardiovascular Disease

Heptares Therapeutics and the University of Cambridge have partnered to investigate a novel target for cardiovascular diseases. Heptares Therapeutics, based in London, develops drugs against historically undruggable G protein-coupled receptors (GPCRs). The company has now announced a new research collaboration with the University of Cambridge focusing on a specific GPCR, the apelin receptor. Heptares will support a […]

January 31, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 31 Jan 2017

Top 5 Biologicals from European Biopharma to Launch in 2017

A new report listing the top drug launches this year reveals the strong performance of biologicals and European biopharma on the drug market. After the worst year in biotech finance, experts seem to agree that the industry will start recovering in 2017. There are still substantial uncertainties, mostly regarding the new US administration. Though a […]

January 31, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

In Depth 31 Jan 2017

Biologicals on the Brain: Biotech in Neurodegenerative Disease

Brain diseases are hard to treat, but biotechs are harnessing a variety of techniques, including immunotherapy and gene therapy, to target neurodegenerative disorders. When Eli Lilly announced that solanezumab, a long anticipated Alzheimer’s antibody, failed in their third attempt at a late stage trial last year, it crushed patients’ hopes and raised doubts about whether […]

January 31, 2017 - 7 minutesmins - By Diana Kwon

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

French Biotech’s Checkpoint Inhibitor Fails Phase II Leukemia Trial

“We want to be the Worldwide Leader in Microbiota”

This PhD-Carrying Musician Tells the Story of Life through Music & Video

Could GM Insects impact the international trade of Organic Food?

Galapagos kicks off a Phase IIa trial for Cystic Fibrosis

Young Belgian Biotech will tackle Fibrosis with a New Grant

Meet these 3 Exciting German Startups Pitching in Aachen Today!

Young German Immune Therapy Biotech expands its Series A Funding

Stem Cell Therapy for Sepsis in Pneumonia advances to Phase II

New British Biotech-Academia Alliance takes on Cardiovascular Disease

Top 5 Biologicals from European Biopharma to Launch in 2017

Biologicals on the Brain: Biotech in Neurodegenerative Disease

Subscribe to our newsletter to get the latest biotech news!